NDA filed to treat refractory herpes.
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy*; D000287:Administration, Topical; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000077404:Cidofovir; D003596:Cytosine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017277:Drug Approval; D006561:Herpes Simplex / Q000188:drug therapy*; D006801:Humans; D063065:Organophosphonates; D009943:Organophosphorus Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D012008:Recurrence; D014481:United States; D014486:United States Food and Drug Administration
D000998:Antiviral Agents; D063065:Organophosphonates; D009943:Organophosphorus Compounds; D003596:Cytosine; D000077404:Cidofovir